Santen Pharmaceutical (4536) Stock Overview
Engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 4536 from our risk checks.
4536 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,740.00 |
| 52 Week High | JP¥2,254.00 |
| 52 Week Low | JP¥1,458.00 |
| Beta | 0.23 |
| 1 Month Change | -10.45% |
| 3 Month Change | -9.54% |
| 1 Year Change | 5.07% |
| 3 Year Change | 21.47% |
| 5 Year Change | 3.69% |
| Change since IPO | 462.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4536 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -7.0% | -4.7% | -0.5% |
| 1Y | 5.1% | 6.4% | 28.3% |
Return vs Industry: 4536 underperformed the JP Pharmaceuticals industry which returned 6.4% over the past year.
Return vs Market: 4536 underperformed the JP Market which returned 28.3% over the past year.
Price Volatility
| 4536 volatility | |
|---|---|
| 4536 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JP Market | 8.8% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 4536 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4536's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 3,968 | Takeshi Ito | www.santen.com/en |
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; cepetaprost, an FP/EP3 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; latanoprost, a prostaglandin Fa derivative emulsified eye drops; netalusdil mesylate, a ROCK/NET inhibitor; Netalus, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative; netalusdyl mesialate/latanoprost, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative that is in phase I clinical trial for the treatment of glaucoma and ocular hypertension area.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| 4536 fundamental statistics | |
|---|---|
| Market cap | JP¥564.81b |
| Earnings (TTM) | JP¥38.68b |
| Revenue (TTM) | JP¥291.84b |
Is 4536 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4536 income statement (TTM) | |
|---|---|
| Revenue | JP¥291.84b |
| Cost of Revenue | JP¥119.23b |
| Gross Profit | JP¥172.61b |
| Other Expenses | JP¥133.94b |
| Earnings | JP¥38.68b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 05, 2026
| Earnings per share (EPS) | 120.41 |
| Gross Margin | 59.15% |
| Net Profit Margin | 13.25% |
| Debt/Equity Ratio | 0% |
How did 4536 perform over the long term?
See historical performance and comparisonDividends
Does 4536 pay a reliable dividends?
See 4536 dividend history and benchmarks| Santen Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2026 |
| Dividend Pay Date | Nov 30 2026 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 81 days |
Does 4536 pay a reliable dividends?
See 4536 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 07:29 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Santen Pharmaceutical Co., Ltd. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |